Dr. Todd A. Gersten, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 812
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc)
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME83684 -
Hematology (Internal Medicine) Physician
FL license ME83684
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Good Samaritan Medical Center West PAlm Beach, FL
- Wellington Regional Medical Center Wellington, FL
Medical groups
- Florida Cancer Specialists and Research Institute, LLC (498 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 812
- Services billed
- 169,732
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, paclitaxel, 1 mg | 12,075 | 16 |
| Injection, aprepitant, 1 mg | 11,700 | 29 |
| Injection, pembrolizumab, 1 mg | 10,800 | 20 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 10,655 | 100 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 8,160 | 13 |
| Injection, iron sucrose, 1 mg | 8,000 | 15 |
| Injection, ferric derisomaltose, 10 mg | 5,600 | 32 |
| Injection, denosumab, 1 mg | 4,620 | 30 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 3,880 | 35 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,339 | 54 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Wellington, FL | 81 |
| Acyclovir Other prescribers in Wellington, FL | 75 |
| Prochlorperazine Maleate Other prescribers in Wellington, FL | 74 |
| Gabapentin Other prescribers in Wellington, FL | 70 |
| Revlimid (lenalidomide) | 62 |
| Hydroxyurea Other prescribers in Wellington, FL | 53 |
| Ondansetron Odt (ondansetron) Other prescribers in Wellington, FL | 49 |
| Anastrozole Other prescribers in Wellington, FL | 41 |
| Escitalopram Oxalate Other prescribers in Wellington, FL | 40 |
| Xarelto (rivaroxaban) Other prescribers in Wellington, FL | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 51 companies reported 256 payments worth $5,529 in total to this clinician.
| Pfizer Inc. | $511 |
|---|---|
| AbbVie Inc. | $395 |
| Janssen Biotech, Inc. | $370 |
| Celgene Corporation | $304 |
| Novartis Pharmaceuticals Corporation | $279 |
| AstraZeneca Pharmaceuticals LP | $264 |
| Merck Sharp & Dohme LLC | $260 |
| Daiichi Sankyo Inc. | $233 |
| Food and Beverage | $5,476 |
|---|---|
| Education | $53.20 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genmab U.S., Inc. Jul 30, 2025 | Education Epkinly · Oncology · in-kind | $20.05 |
| Pfizer Inc. Feb 21, 2025 | Education ELREXFIO · ONCOLOGY · in-kind | $17.16 |
| Legend Biotech USA Inc. Aug 4, 2025 | Education CARVYKTI · Oncology · in-kind | $15.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 8 companies. The companies reported $404,043 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage…
E.r. Squibb & Sons, L.l.c. - A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
Janssen Research & Development, LLC - A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Ch…
Janssen Research & Development, LLC - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treat…
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Geno…
AstraZeneca Pharmaceuticals LP - An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development - An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or meta…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.